首页> 外文会议>International Symposium on Ceramics in Medicine >TricOs~(TM) and Fibrin Sealant Combined for Bone Defect Filling: From Pre-Clinical Tests to Prospective Clinical Study. Preliminary human data
【24h】

TricOs~(TM) and Fibrin Sealant Combined for Bone Defect Filling: From Pre-Clinical Tests to Prospective Clinical Study. Preliminary human data

机译:TRICOS〜(TM)和纤维蛋白密封剂组合用于骨缺损填充:从临床前测试到前瞻性临床研究。初步人体数据

获取原文

摘要

The association of TricOs~(TM) (Macroporous Biphasic Ceramic Phosphate MBCP granules) and the fibrin sealant FS VH S/D 4, has been developed to answer a challenging request of orthopaedic surgeons: a biocompatible, osteogenic, mouldable, and self-hardening bone substitute able to fill randomly shaped bone defects. The aims of this study was the evaluation of the performance and safety of the bioactive bone substitute TricOs~(TM) associated with a fibrin sealant in regeneration of functional bone. The pre-clinical tests were conducted to optimize MBCP granules size and ratio MBCP-FS VH S/D 4 (sheep maxillary sinus grafting, femoral epiphysis defect in rabbits, long bone defects in sheep). A clinical study design was set up as an exploratory prospective French multicentric phase II study sponsored by INSERM (Institut National de la Sante et de la Recherche Medicale). The application was the TOV (Tibial Osteotomy of Valgisation) using osteosynthesis and bone substitute: TricOs~(TM) mixed with the fibrin sealant (FS VH S/D 4) for filling the space created. The follow up is 13 months with safety checks, clinical assessments, high-sensitivity X-ray, and CT-scan imaging. A bone sample will be collected from the reconstructed area at 12 months, during the osteosynthesis material removal surgery. The principal criterion is CT-scan imaging performed 12 months after TOV surgery, before material removal, to assess qualitative and quantitative bone reconstruction. Animals' studies demonstrate that the biomaterial is safe to use and shows osteoconductive properties, granules resorption and bone ingrowth at the expenses of the implants. As for clinical trial, 7 patients are today included in the study: This paper present the first results obtained from X-ray imaging during follow up.
机译:已经开发了TRICOS〜(TM)(大孔双相陶瓷磷酸盐MBCP颗粒)和纤维蛋白密封剂FS VH S / D 4的关联,以应对骨科外科医生的具有挑战性的要求:生物相容的,成骨,可模态和自硬化骨替代能够填充随机形状的骨缺陷。本研究的目的是评估与纤维蛋白密封剂在功能骨再生中的生物活性骨替代三语〜(TM)的性能和安全性评估。进行了前临床前试验以优化MBCP颗粒尺寸和比率MBCP-FS VH S / D 4(兔子羊颌骨分析缺陷,羊的长骨缺陷)。建立了一个临床研究设计作为伊斯明(Institut National de La Sante et de La Recherche Medice)赞助的探索性预期法国多中心第二阶段研究。该应用是使用骨合成和骨替代方法的TOV(胫骨骨质分子术):与纤维蛋白密封剂(FS VH S / D 4)混合的TRICOS〜(TM)用于填充所产生的空间。随访是13个月,安全检查,临床评估,高灵敏度X射线和CT扫描成像。在骨合成材料去除手术期间,将在12个月内从重建区域收集骨样品。主要标准是CT-SCAN成像在术后12个月内进行,在材料去除之前,评估定性和定量骨重建。动物的研究表明,生物材料安全使用并显示出植物费用的骨质导电性能,颗粒体吸收和骨骼注重。至于临床试验,今天将7名患者包括在研究中:本文提出了在随访期间从X射线成像获得的第一个结果。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号